TipRanks
Advertisement
Advertisement

DE:7OC0 Stock Latest News

Insight Molecular Diagnostics Revises Chronix Royalty Agreement Terms
Company AnnouncementsInsight Molecular Diagnostics Revises Chronix Royalty Agreement Terms
20d ago
8K
IMDX
Insight Molecular Diagnostics initiated with a Buy at Lucid Capital
PremiumThe Fly
Insight Molecular Diagnostics initiated with a Buy at Lucid Capital
2M ago
IMDX
Insight Molecular Diagnostics Earnings Call Balances Risk
PremiumCompany Announcements
Insight Molecular Diagnostics Earnings Call Balances Risk
2M ago
IMDX
Insight Molecular Diagnostics: Buy Rating Reiterated on Growing Clinical Adoption of Donor-Derived cfDNA Testing and Unchanged $9 Price Target
PremiumRatings
Insight Molecular Diagnostics: Buy Rating Reiterated on Growing Clinical Adoption of Donor-Derived cfDNA Testing and Unchanged $9 Price Target
2M ago
IMDX
Michael Matson Reiterates Buy on IMDX, Citing Regulatory Progress, GraftAssure Platform Expansion, and Solid Cash Runway Ahead of Expected 2026 De Novo Approval
PremiumRatings
Michael Matson Reiterates Buy on IMDX, Citing Regulatory Progress, GraftAssure Platform Expansion, and Solid Cash Runway Ahead of Expected 2026 De Novo Approval
2M ago
IMDX
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay
PremiumCompany AnnouncementsInsight Molecular Nears FDA Authorization for GraftAssureDx Assay
2M ago
8K
IMDX
Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c)
Premium
The Fly
Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c)
2M ago
IMDX
IMDX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
IMDX Earnings this Week: How Will it Perform?
2M ago
IMDX
Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay
PremiumThe Fly
Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay
3M ago
IMDX
Insight Molecular Diagnostics Shareholders Back Board and Incentive Plan
PremiumCompany Announcements
Insight Molecular Diagnostics Shareholders Back Board and Incentive Plan
4M ago
8K
IMDX
Insight Molecular Diagnostics Balances Progress and Cash Burn
PremiumCompany Announcements
Insight Molecular Diagnostics Balances Progress and Cash Burn
5M ago
IMDX
OncoCyte’s Earnings Call Maps Risky Path to Launch
PremiumCompany Announcements
OncoCyte’s Earnings Call Maps Risky Path to Launch
5M ago
IMDX
Insight Molecular Diagnostics Maintained at Buy as GraftAssure Platform Gains Traction; $9 Price Target Reaffirmed
PremiumRatingsInsight Molecular Diagnostics Maintained at Buy as GraftAssure Platform Gains Traction; $9 Price Target Reaffirmed
5M ago
IMDX
Insight Molecular Corrects Bylaws Disclosure in Annual Report
Premium
Company Announcements
Insight Molecular Corrects Bylaws Disclosure in Annual Report
5M ago
8K
IMDX
Insight Molecular Diagnostics: Building Momentum with GraftAssure Platform and Favorable Risk‑Reward Supporting Buy Rating
Premium
Ratings
Insight Molecular Diagnostics: Building Momentum with GraftAssure Platform and Favorable Risk‑Reward Supporting Buy Rating
6M ago
IMDX
OncoCyte Earnings Call: GraftAssureDx Drives Pivot
PremiumCompany Announcements
OncoCyte Earnings Call: GraftAssureDx Drives Pivot
6M ago
IMDX
Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet
PremiumRatings
Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet
7M ago
IMDX
Insight Molecular Diagnostics submits GraftAssureDx for FDA review
PremiumThe Fly
Insight Molecular Diagnostics submits GraftAssureDx for FDA review
7M ago
IMDX
Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year
PremiumThe Fly
Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year
7M ago
IMDX
OCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsOCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
7M ago
IMDX
Insight Molecular Diagnostics highlights publication of study on GraftAssure
Premium
The Fly
Insight Molecular Diagnostics highlights publication of study on GraftAssure
7M ago
IMDX
Insight Molecular Diagnostics completes milestones advancing GraftAssureDx
Premium
The Fly
Insight Molecular Diagnostics completes milestones advancing GraftAssureDx
7M ago
IMDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >